Xeris Pharmaceuticals, Inc. (XERS) News

Xeris Pharmaceuticals, Inc. (XERS): $1.50

-0.04 (-2.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter XERS News Items

XERS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XERS News Highlights

  • For XERS, its 30 day story count is now at 5.
  • Over the past 16 days, the trend for XERS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about XERS are DRUG.

Latest XERS News From Around the Web

Below are the latest news stories about Xeris Biopharma Holdings Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.

Leerink Partners Thinks Xeris Pharmaceuticals’ Stock is Going to Recover

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $2.57, close to its 52-week low of $1.77. According to TipRanks.com, Ruiz 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $6.

Howard Kim on TipRanks | February 16, 2022

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00pm Eastern Time. A live webcast of the fireside chat will be available o

Business Wire | February 9, 2022

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

CHICAGO, January 31, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Recorlev® (levoketoconazole) is now available for prescription. The U.S. Food and Drug Administration (FDA) approved Recorlev on December 31, 2021 for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surger

Yahoo | January 31, 2022

Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover

Mizuho Securities analyst Vamil Divan maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $8.00. The company's shares closed last Friday at $2.22, close to its 52-week low of $1.77. According to TipRanks.com, Divan has 0 stars on 0-5 stars ranking scale with an average return of -3.9% and a 44.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Xeris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.85.

Catie Powers on TipRanks | January 18, 2022

Xeris Biopharma Eyes High End Of FY21 Sales Outlook

Xeris Biopharma Holdings Inc (NASDAQ: XERS ) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million. "2022 is off to a good Full story available on Benzinga.com

Benzinga | January 18, 2022

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole). Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Cushing's syndrome, a disease assoc

Yahoo | January 13, 2022

Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Yahoo | January 7, 2022

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

CHICAGO, January 06, 2022--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Biopharma, will present an overview of the company and highlight recent events, including the FDA approval of Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual conference being held January 1

Yahoo | January 6, 2022

Xeris Pharmaceuticals (XERS) Received its Third Buy in a Row

After Piper Sandler and H.C. Wainwright gave Xeris Pharmaceuticals (NASDAQ: XERS) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan maintained a Buy rating on Xeris Pharmaceuticals today and set a price target of $8.00. The company's shares closed last Monday at $2.81. According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.9% and a 47.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $5.

Brian Anderson on TipRanks | January 3, 2022

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

CHICAGO, January 03, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ("Xeris" or the "Company"), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement (the "Private Placement") with an affiliate of Armistice Capital, LLC ("Armistice") for aggregate gross proceeds of appr

Yahoo | January 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4448 seconds.